IL17A and musculoskeletal system disorder: While patients with established PsA and psoriasis patients with a very early form of musculoskeletal disease fundamentally differ in their PROs and cluster differently, effective therapy, like in this case, IL-17A inhibition by secukinumab abolished these clusters and redistributed patients based on their concordant or discordant physical and mental outcomes.